JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

NeoGenomics Inc

Slēgts

5.62 -0.88

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

5.54

Max

5.86

Galvenie mērījumi

By Trading Economics

Ienākumi

-19M

-45M

Pārdošana

13M

181M

Peļņas marža

-24.867

Darbinieki

2,200

EBITDA

-41M

-48M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+63.84% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-99M

732M

Iepriekšējā atvēršanas cena

6.5

Iepriekšējā slēgšanas cena

5.62

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

NeoGenomics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. aug. 16:50 UTC

Galvenie tirgus virzītāji

Verb Technology Shares Double After Private Placement, Intent to Buy Cryptocurrency

2025. g. 31. jūl. 20:58 UTC

Peļņas

Coinbase Global Misses on 2Q Revenue, Outlook

2025. g. 31. jūl. 20:37 UTC

Peļņas

MicroStrategy Swings to 2Q Profit on Bitcoin Gains

2025. g. 29. jūl. 17:53 UTC

Galvenie tirgus virzītāji

ZOOZ Shares Down; Plans $180 Million Private Placement for Bitcoin Reserve Strategy

2025. g. 29. jūl. 16:36 UTC

Galvenie tirgus virzītāji

Antelope Enterprise Shares Drop After Securities Purchase Agreement

2025. g. 5. aug. 13:55 UTC

Tirgus saruna

Bitcoin Is Being Treated as a Portfolio Diversifier -- Market Talk

2025. g. 5. aug. 08:43 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 5. aug. 08:43 UTC

Tirgus saruna

Bitcoin Eases Amid Tariff Uncertainty -- Market Talk

2025. g. 4. aug. 08:37 UTC

Tirgus saruna

Bitcoin Recovers as U.S. Rate-Cut Bets Rise -- Market Talk

2025. g. 1. aug. 22:31 UTC

Peļņas

MicroStrategy Stock Drops 9%. New Equity Guidelines Could Be the Reason. -- Barrons.com

2025. g. 1. aug. 08:22 UTC

Tirgus saruna

Bitcoin Falls to Three-Week Low After Tariff News, Ahead of U.S. Data -- Market Talk

2025. g. 31. jūl. 21:26 UTC

Peļņas

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

2025. g. 31. jūl. 20:43 UTC

Peļņas

Riot Platforms 2Q Produced 1,426 Bitcoin, as Compared to 844 During the Same 3-Mo Period in 2024 >RIOT

2025. g. 31. jūl. 20:43 UTC

Peļņas

Riot Platforms 2Q Rev $153M >RIOT

2025. g. 31. jūl. 20:31 UTC

Peļņas

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

2025. g. 31. jūl. 15:30 UTC

Peļņas

What MicroStrategy Earnings Tell Us About the Current State of Crypto Mania -- Barrons.com

2025. g. 31. jūl. 15:20 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Coinbase Reports Earnings This Afternoon. What to Watch. -- Barrons.com

2025. g. 31. jūl. 07:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 31. jūl. 07:36 UTC

Tirgus saruna

Bitcoin Modestly Higher But Stays Below Key $120,000 Level -- Market Talk

2025. g. 30. jūl. 07:28 UTC

Tirgus saruna

Bitcoin Edges Higher But Remains Stuck in a Range -- Market Talk

2025. g. 29. jūl. 21:45 UTC

Tirgus saruna
Peļņas

Visa Views Stablecoin as Growth Opportunity -- Market Talk

2025. g. 29. jūl. 21:21 UTC

Peļņas

Visa CEO: U.S. Spend Growth Remained Strong in 2Q, No Noticeable Effects From Tariff

2025. g. 29. jūl. 21:19 UTC

Peļņas

Visa CEO: Consumers Have Used Visa to Spend $25B in Cryptocurrencies Since 2020

2025. g. 29. jūl. 21:17 UTC

Peļņas

Visa Is Best Way to Spend Money Using Stablecoins, CEO Says

2025. g. 29. jūl. 21:17 UTC

Peļņas

Visa CEO: We Support Genius Act, Believe Stablecoins Can Solve Problems for Certain Use Cases

2025. g. 29. jūl. 17:38 UTC

Galvenie tirgus virzītāji

ZOOZ Shares Down; Plans $180M Private Placement for Bitcoin Reserve Strategy

2025. g. 29. jūl. 14:05 UTC

Peļņas

SoFi Stock Pops on Outlook Raise as Members Keep Piling In -- Update

2025. g. 29. jūl. 12:09 UTC

Tirgus saruna

Stablecoin Regulation Could Support Dollar -- Market Talk

2025. g. 29. jūl. 09:43 UTC

Tirgus saruna

Ethereum Could Rise Further on Corporate Treasury Purchases -- Market Talk

2025. g. 29. jūl. 08:24 UTC

Tirgus saruna

Bitcoin Rises Slightly After U.S.-EU Trade Deal -- Market Talk

Salīdzinājums

Cenas izmaiņa

NeoGenomics Inc Prognoze

Cenas mērķis

By TipRanks

63.84% augšup

Prognoze 12 mēnešiem

Vidējais 9.29 USD  63.84%

Augstākais 12 USD

Zemākais 8 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi NeoGenomics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

4

Pirkt

7

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

7.7 / 10.27Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.